Fluvoxamine used to treat COVID-19 resulting in theophylline toxicity from CYP 1A2 drug–drug interaction

Jon B. Colea Minnesota Poison Control System, Hennepin Healthcare, Minneapolis, MN, USA;b Department of Emergency Medicine, Hennepin Healthcare, Minneapolis, MN, USA;c Department of Emergency Medicine, University of Minnesota Medical School, Minneapolis, MN, USACorrespondence[email protected]

https://orcid.org/0000-0002-7714-8826

Rebecca B. Meinersa Minnesota Poison Control System, Hennepin Healthcare, Minneapolis, MN, USA

Stacey A. Bangha Minnesota Poison Control System, Hennepin Healthcare, Minneapolis, MN, USA

https://orcid.org/0000-0002-0665-9231

"Fluvoxamine used to treat COVID-19 resulting in theophylline toxicity from CYP 1A2 drug–drug interaction." Clinical Toxicology, 60(8), pp. 985–986

Authors contribution

J. B. C. conceived and designed the manuscript. R. B. M. and S. A. B. provided patient care and critically reviewed the manuscript. J. B. C. drafted the manuscript, and all authors contributed substantially to its revision. J. B. C. takes responsibility for the paper as a whole.

Disclosure statement

All authors report no conflicts of interest.

Grant/funding

This project did not receive external funding.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Fluvoxamine used to treat COVID-19 resulting in theophylline toxicity from CYP 1A2 drug–drug interaction

Information for

Open access

Opportunities

Help and information

Fluvoxamine used to treat COVID-19 resulting in theophylline toxicity from CYP 1A2 drug–drug interaction

Authors contribution

Disclosure statement

Grant/funding

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature